Latest news with #relacorilant
Yahoo
07-07-2025
- Business
- Yahoo
Corcept Therapeutics (CORT) Announces Pivotal Data from Phase 3 ROSELLA Trial
Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. On June 2, Corcept Therapeutics Incorporated (NASDAQ:CORT) announced pivotal data from its Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the American Society of Clinical Oncology Annual Meeting. A biologist in a lab coat studying a culture of cells to find a cure for metabolic disorders. According to the release, ROSELLA met its primary endpoint of improved progression-free survival according to assessment by blinded independent central review (PFS-BICR). A 30% reduction in disease progression risk was recorded in patients who received relacorilant in addition to nab-paclitaxel chemotherapy as compared to those who received nab-paclitaxel monotherapy only. The results also showed that relacorilant plus nab-paclitaxel was well-tolerated and exhibited a comparable safety profile between treatment arms. Adding relacorilant did not cause a rise in patients' safety burden. In fact, patients who were administered relacorilant plus nab-paclitaxel experienced a lower incidence of ascites (5.3%) compared to those who received nab-paclitaxel alone (10.5%). The occurrence of abdominal paracenteses during treatment was also lower for the former patients. Corcept Therapeutics Incorporated (NASDAQ:CORT) is a biopharmaceutical company that develops and commercializes therapies that adjust the effects of cortisol, a hormone that regulates various bodily functions. The company's flagship product, Korlym, is FDA-approved for the treatment of Cushing's syndrome, a disorder characterized by excessive cortisol production. While we acknowledge the potential of CORT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤
Medscape
03-06-2025
- Business
- Medscape
Relacorilant + Nab-Paclitaxel Beneficial in Ovarian Cancer
Relacorilant, a selective glucocorticoid receptor antagonist, combined with nab-paclitaxel significantly improved progression-free survival in women with platinum-resistant ovarian cancer. The interim analysis also showed meaningful improvement in overall survival, with median survival extending from 11.50 to 15.97 months. METHODOLOGY: While platinum-based chemotherapy is initially effective, about 70% of patients experience disease relapse that becomes platinum-resistant. Relacorilant, a selective glucocorticoid receptor antagonist, has demonstrated synergy with paclitaxel in nonclinical tumor models. The combination with nab-paclitaxel was chosen for this study because it does not require corticosteroid coadministration. Researchers conducted a randomized, controlled, open-label, phase 3 trial (ROSELLA [GOG-3073/ENGOT-ov72]) at 117 hospitals and community oncology treatment centers across 14 countries in Australia, Europe, Latin America, North America, and South Korea. Participants included 381 patients aged 18 years or older with confirmed platinum-resistant epithelial ovarian, primary peritoneal, or fallopian tube cancer; up to three previous lines of anticancer therapy; and measurable disease as per Response Evaluation Criteria in Solid Tumors (version 1.1). Analysis involved comparing relacorilant (150 mg orally the day before, of, and after nab-paclitaxel infusion) plus nab-paclitaxel (80 mg/m2 intravenously on days 1, 8, and 15 of each 28-day cycle) with nab-paclitaxel monotherapy (100 mg/m2 on the same schedule). TAKEAWAY: Patients receiving relacorilant plus nab-paclitaxel showed improved progression-free survival compared with those receiving nab-paclitaxel monotherapy (hazard ratio [HR], 0.70; 95% CI, 0.54-0.91; median, 6.54 months vs 5.52 months; stratified log-rank P = .0076). = .0076). Interim analysis revealed improved overall survival with relacorilant plus nab-paclitaxel vs nab-paclitaxel monotherapy (HR, 0.69; 95% CI, 0.52-0.92; median, 15.97 months vs 11.50 months; log-rank P = .0121). = .0121). Safety profiles were comparable between the groups when adjusted for nab-paclitaxel exposure, with no new safety signals observed. IN PRACTICE: 'Combined with the evidence from previous studies, our study supports relacorilant plus nab-paclitaxel as a potential new standard of care for patients with platinum-resistant ovarian cancer, without the need for biomarker selection. This study is the first positive clinical trial conducted with registrational intent for a selective glucocorticoid receptor antagonist in patients with cancer,' authors of the study wrote. SOURCE: Lead author Alexander B. Olawaiye, MD, of the University of Pittsburgh School of Medicine and UPMC Magee-Womens Hospital, both in Pittsburgh, presented the results of the study at American Society of Clinical Oncology (ASCO) 2025. A paper on the study was published online in The Lancet on June 2. LIMITATIONS: The open-label design and applicability to patients with more than three lines of anticancer therapy were noted as limitations. While the risk of bias in progression-free survival assessment was mitigated by using blinded independent central review and a dual primary endpoint of overall survival, the median duration of the follow-up for overall survival was less than the estimated median overall survival in the relacorilant combination group at interim analysis. DISCLOSURES: The study was funded by Corcept Therapeutics. The authors reported that adverse events were graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (version 5.0), with relatedness determined by the investigators. The funding source supported trial conduct, patient enrollment, and drug supply. The analysis, interpretation, writing, and submission decisions were the responsibility of the authors.
